Avadel Pharmaceuticals Plc Stock Debt To Equity
| AVDL Stock | USD 18.82 0.52 2.84% |
Avadel Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Avadel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Avadel Stock. The fundamental analysis module provides a way to measure Avadel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avadel Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.38 | 0.36 |
Avadel | Debt To Equity |
Avadel Pharmaceuticals PLC Company Debt To Equity Analysis
Avadel Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Avadel Pharmaceuticals Debt To Equity | 2.63 % |
Most of Avadel Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avadel Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avadel Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Avadel Pharmaceuticals is extremely important. It helps to project a fair market value of Avadel Stock properly, considering its historical fundamentals such as Debt To Equity. Since Avadel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avadel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avadel Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Avadel Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Avadel Pharmaceuticals PLC has a Debt To Equity of 2.627%. This is 95.09% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 94.61% higher than that of the company.
Avadel Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avadel Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avadel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Avadel Pharmaceuticals by comparing valuation metrics of similar companies.Avadel Pharmaceuticals is currently under evaluation in debt to equity category among related companies.
Avadel Fundamentals
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (1.28) % | ||||
| Current Valuation | 1.63 B | ||||
| Shares Outstanding | 96.12 M | ||||
| Shares Owned By Insiders | 4.61 % | ||||
| Shares Owned By Institutions | 58.49 % | ||||
| Number Of Shares Shorted | 10.61 M | ||||
| Price To Earning | 61.46 X | ||||
| Price To Book | 16.52 X | ||||
| Price To Sales | 51.79 X | ||||
| Revenue | 27.96 M | ||||
| Gross Profit | 16.59 M | ||||
| EBITDA | (136.08 M) | ||||
| Net Income | (160.28 M) | ||||
| Cash And Equivalents | 104.12 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 35.38 M | ||||
| Debt To Equity | 2.63 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (132.87 M) | ||||
| Short Ratio | 14.32 X | ||||
| Earnings Per Share | (2.00) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 23.1 | ||||
| Number Of Employees | 154 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 3.51 B | ||||
| Total Asset | 261.13 M | ||||
| Retained Earnings | (745.5 M) | ||||
| Working Capital | 97.35 M | ||||
| Current Asset | 177.85 M | ||||
| Current Liabilities | 59.19 M | ||||
| Net Asset | 261.13 M |
About Avadel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avadel Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avadel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avadel Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Avadel Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Avadel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avadel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Avadel Stock
| 0.7 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
Moving against Avadel Stock
| 0.8 | TKNO | Alpha Teknova Financial Report 8th of May 2024 | PairCorr |
| 0.73 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.69 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.69 | RGC | Regencell Bioscience | PairCorr |
| 0.69 | PROCW | Procaps Group SA | PairCorr |
The ability to find closely correlated positions to Avadel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Avadel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Avadel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Avadel Pharmaceuticals PLC to buy it.
The correlation of Avadel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Avadel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Avadel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Avadel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Avadel Pharmaceuticals Piotroski F Score and Avadel Pharmaceuticals Altman Z Score analysis. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Avadel Stock analysis
When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.349 | Quarterly Revenue Growth (1.00) | Return On Assets (0.58) | Return On Equity (4.81) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.